Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 3, 2012, Pages 298-303

  Kim, Ga Eon ^a   Kim, Jo Heon ^b   Lee, Kyung Hwa ^a   Choi, Yoo Duck ^a   Lee, Ji Shin ^a   Lee, Jae Hyuk ^a   Nam, Jong Hee ^a   Choi, Chan ^a   Park, Min Ho ^a   Yoon, Jung Han ^a  

^a Chonnam National University Medical School   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

Author keywords

breast tumor; matrix metalloproteases; phyllodes; tissue inhibitors of metalloproteases

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STROMA CELL;

ADULT; BREAST; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MATRIX METALLOPROTEINASE 14; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PHYLLODES TUMOR; PROGNOSIS; PROTEIN ISOFORMS; STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84859889675     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318235a132     Document Type: Article

References (30)

1. Rosen PP. Fibroepithelial neoplasms. In: Rosen PP, ed. Rosen's Breast Pathology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009:187-229.
2. Bellocq JP, Magro G. Fibroepithelial tumors. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumors: Tumors of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:99-103.
3. Moffat CJ, Pinder SE, Dixon AR, et al. Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology. 1995;27:205-218.
4. Ang MK, Ooi AS, Thike AA, et al. Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Res Treat. 2011;129:319-329.
5. Kleer CG, Giordano TJ, Braun T, et al. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Mod Pathol. 2001;14:185-190. (Pubitemid 32246822)
6. Sawyer EJ, Poulsom R, Hunt FT, et al. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol. 2006;200:59-64. (Pubitemid 36592637)
7. Tse GM, Lui PC, Lee CS, et al. Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum Pathol. 2004;35:1053-1057. (Pubitemid 39165335)
8. Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol. 2005;18:1527-1534. (Pubitemid 41670650)
9. Tse GM, Tsang AK, Putti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol. 2005;58:185-189. (Pubitemid 40193805)
10. Esposito NN, Mohan D, Brufsky A, et al. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med. 2006;130:1516-1521. (Pubitemid 44520719)
11. Kersting C, Kuijper A, Schmidt H, et al. Amplifications of the epidermal growth factor receptor gene (EGFR) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest. 2006;86:54-61. (Pubitemid 43250968)
12. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997; 89:1260-1270. (Pubitemid 27371946)
13. Vu T, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123-2133.
14. Fassina G, Ferrari N, Brigati C, et al. Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis. 2000;18:111-120. (Pubitemid 32165244)
15. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245-2252. (Pubitemid 34311378)
16. Deryugina EI, Quigley JP. Matrix metalloproteinases and metastasis. Cancer Metastasis Rev. 2006;25:9-34.
17. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des. 2007;13:333-346. (Pubitemid 46085282)
18. Vizoso FJ, Gonzá lez LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96:903-911. (Pubitemid 46452295)
19. McGowan PM, Duffy MJ.Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008;19:1566-1572.
20. Figueira RC, Gomes LR, Neto JS, et al. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 2009;9:20.
21. Kim HS, Youm HR, Lee JS, et al. Correlation between cyclooxygenase- 2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer. 2003;42:163-170.
22. Makretsov NA, Hayes M, Carter BA, et al. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 2007;20:84-89. (Pubitemid 44967953)
23. Tse GM, Tsang AK, Putti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol. 2005;58:185-189. (Pubitemid 40193805)
24. Tsai WC, Jin JS, Yu JC, et al. CD10, actin, and vimentin expression in breast phyllodes tumors correlates with tumor grades of the WHO grading system. Int J Surg Pathol. 2006;14:127-131.
25. Fu X, Parks WC, Heinecke JW. Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol. 2008;19:2-13. (Pubitemid 350235984)
26. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252-257. (Pubitemid 32223594)
27. Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714-723. (Pubitemid 47106199)
28. Ohuchi E, Imai K, Fujii Y, et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 1997;272:2446-2451. (Pubitemid 27058534)
29. Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007;9:893-904. (Pubitemid 47190444)
30. Tetu B, Brisson J, Wang CS, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res. 2006;8:R28.